Dario A. Paggiarino - 26 Jan 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Medical Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
26 Jan 2024
Net transactions value
-$621,492
Form type
4
Filing time
30 Jan 2024, 16:53:11 UTC
Previous filing
29 Jan 2024
Next filing
13 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $201,356 +15,609 +43% $12.90 52,114 26 Jan 2024 Direct
transaction EYPT Common Stock Options Exercise $670 +51 +0.1% $13.13 52,165 26 Jan 2024 Direct
transaction EYPT Common Stock Options Exercise $442,021 +33,665 +65% $13.13 85,830 26 Jan 2024 Direct
transaction EYPT Common Stock Sale $1,296 -51 -0.06% $25.41 85,779 26 Jan 2024 Direct F1
transaction EYPT Common Stock Sale $396,572 -15,609 -18% $25.41 70,170 26 Jan 2024 Direct F1
transaction EYPT Common Stock Sale $867,672 -33,665 -48% $25.77 36,505 26 Jan 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -51 -0.1% $0.000000 51,253 26 Jan 2024 Common Stock 51 $13.13 Direct F3
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -33,665 -66% $0.000000 17,588 26 Jan 2024 Common Stock 33,665 $13.13 Direct F3
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -15,609 -94% $0.000000 1,026 26 Jan 2024 Common Stock 15,609 $12.90 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $26.62. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.
F4 The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020